Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics
Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies for serious medical conditions driven by the immune system. Jeito continues to build a strong portfolio of companies with groundbreaking therapies in areas of high unmet need. Paris, France, 29 November […]